Citation(s)
- Carlsson A, Waters N, Waters S, Carlsson ML
Network interactions in schizophrenia - therapeutic implications. Brain Res Brain Res Rev. 2000 Mar;31(2-3):342-9. Review.
- Carlsson M, Carlsson A
Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease. Trends Neurosci. 1990 Jul;13(7):272-6. Review.
- Coyle JT
The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. 1996 Jan-Feb;3(5):241-53. Review.
- Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA
Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry. 2000 Jul;157(7):1141-9.
- Goff DC, Coyle JT
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001 Sep;158(9):1367-77. Review.
- Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, Freudenreich O, Evins AE, Yovel I, Zhang H, Schoenfeld D
A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl). 2005 Apr;179(1):144-50. Epub 2004 Oct 21.
- Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, Lindenmayer JP, Suckow R, Zukin SR
Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2001 Dec;4(4):385-91.
- Javitt DC, Zukin SR
Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991 Oct;148(10):1301-8. Review.
- Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, Chen PW, Tsai G
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry. 2006 Sep 15;60(6):645-9. Epub 2006 Jun 14.
- Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Perng CH, Tsai GE
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008 Jan 1;63(1):9-12. Epub 2007 Jul 20.
- Law AJ, Deakin JF
Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport. 2001 Sep 17;12(13):2971-4.
- McBain CJ, Mayer ML
N-methyl-D-aspartic acid receptor structure and function. Physiol Rev. 1994 Jul;74(3):723-60. Review.
- Olney JW, Newcomer JW, Farber NB
NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 1999 Nov-Dec;33(6):523-33. Review.
- Tsai G, Lane HY, Yang P, Chong MY, Lange N
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004 Mar 1;55(5):452-6.
- Tsai G, van Kammen DP, Chen S, Kelley ME, Grier A, Coyle JT
Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol Psychiatry. 1998 Oct 15;44(8):667-74.
- Tuominen HJ, Tiihonen J, Wahlbeck K
Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003730. Review.
- West AR, Floresco SB, Charara A, Rosenkranz JA, Grace AA
Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann N Y Acad Sci. 2003 Nov;1003:53-74. Review.
- Yurgelun-Todd DA, Coyle JT, Gruber SA, Renshaw PF, Silveri MM, Amico E, Cohen B, Goff DC
Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res. 2005 Jan 30;138(1):23-31.
- Zafra F, Aragón C, Olivares L, Danbolt NC, Giménez C, Storm-Mathisen J
Glycine transporters are differentially expressed among CNS cells. J Neurosci. 1995 May;15(5 Pt 2):3952-69.
Effect of Sarcosine on Symptomatology, Quality of Life, Cognitive and Sexual Functioning, Blood Levels of Sarcosine, Glycine, BDNF and MMP-9, Oculomotor, Brain Metabolism and Oxidative Stress Parameters in Schizophrenia.
Details for clinical trial NCT01503359
